<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21585">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01763112</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT01763112</nct_id>
  </id_info>
  <brief_title>Training With Whole Body Vibration Device in Patients With PAH</brief_title>
  <acronym>GALILEO-PAH</acronym>
  <official_title>Influence of Training With Whole Body Vibration Device (Galileo) on Quality of Life (QoL), Exercise Capacity, as Well as on the Effects of Muscle Power and Muscle Function in Patients With Pulmonal Arterial Hypertension (PAH). (GALILEO PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universität Köln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universität Köln</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title of study / project: Influence of training with whole body vibration device on Quality
      of Life (QoL), exercise capacity, as well as on the effects of muscle power and muscle
      function in patients with pulmonal arterial hypertension (PAH). Background and rationale for
      the proposal:Capacity and the ability to exercise, in patients with PAH is limited. There is
      a few investigations evaluating the effects of the training with whole body vibration (wbv)
      in adults. It was shown that wbv-training could improve muscle power,  QoL,  body balance
      and  had positive effects on the neuromuscular system. Primary scientific question
      addressed:Changes in muscle power, changes in 6-Minute Walk Distance (6MWD) and changes in
      QoL are to be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Open Monocentric prospective randomized observational trial Study arms:
      Treatment group (4-weeks wbv training) planned 20 patients Control group: planned 20
      patients Endpoint (-s): Changes in muscle power, changes in 6-Minute Walk Distance (6MWD),
      changes in QoL changes in peak VO2 (bike exercise test)

      Major study procedures:

      Blood samples, vital parameters, questionnaires, echocardiography, lung function test, blood
      gas analysis, bike exercise test, 6-Minute Walk test, ECG, Chair rising test, power plate
      measurement, walk across test
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>changes in 6-Minute Walk Distance (6MWD)</measure>
    <time_frame>baseline and week 4</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of life</measure>
    <time_frame>baseline and week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in peak Vo2</measure>
    <time_frame>baseline and week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in muscle power</measure>
    <time_frame>baseline and week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pulmonary Artery Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will not do any specific training baseline and week 4 investigation will be done only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise Group Galileo PAH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exercise Group Galileo PAH</intervention_name>
    <description>The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks</description>
    <arm_group_label>Exercise Group Galileo PAH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women age 18-90 years

          -  Signed informed consent

          -  Symptomatic PAH (idiopathic, hereditary or associated with systemic scleroderma)

          -  Invasively confirmed PAH

          -  6MWT  ≥ 50 m

          -  Stable specific therapy for at least 2 months

          -  Ability to perform bike test

          -  Ability to perform wbv training

          -  NYHA/WHO-FC II-III

        Exclusion Criteria:

          -  any other PAH/PH than idiopathic, hereditary or associated with systemic scleroderma

          -  Rehabilitation or other training concept  performed within 2 months before inclusion

          -  pregnancy

          -  acute thrombosis

          -  newly implanted Hip or Knee

          -  recent bone fracture

          -  Disability to confirm consent

          -  NYHA/WHO-FC IV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Gerhardt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik III für Innere Medizin Uniklinik Köln</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Rosenkranz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik III für Innere Medizin der Uniklinik Köln</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felix Gerhardt, PhD</last_name>
    <phone>+49221478</phone>
    <phone_ext>89413</phone_ext>
    <email>felix.gerhardt@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Rosenkranz, PhD</last_name>
    <phone>+49221478</phone>
    <phone_ext>32401</phone_ext>
    <email>stephan.rosenkranz@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spezialambulanz für pulmonale Hypertonie Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <state>NRW</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Gerhardt, PhD</last_name>
      <phone>+49221478</phone>
      <phone_ext>89413</phone_ext>
      <email>felix.gerhardt@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Felix Gerhardt, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 7, 2013</lastchanged_date>
  <firstreceived_date>January 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universität Köln</investigator_affiliation>
    <investigator_full_name>Felix Gerhardt</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Influence of training with whole body vibration device</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
